CERo Therapeutics receives Nasdaq bid price deficiency notice; effects 1-for-20 reverse split

CERO THERAPEUTICS HOLDINGS, INC.

Received Nasdaq notice on June 11, 2025: bid price below $1.00 for 30 consecutive business days (Apr 25–Jun 9).
Not eligible for standard compliance period due to prior reverse stock splits; plans to request a hearing.
Effected 1-for-20 reverse stock split on June 13, 2025; closing bid price was $7.31.
No assurance that bid price will remain above $1.00 or that hearing will grant continued listing.
Common stock (CERO) and warrants (CEROW) continue trading on Nasdaq pending hearing outcome.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.